Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: July 8th 2022 | Updated: September 28th 2024
Identifying Second-Line Options for NSCLC With EGFR Exon 20 Insertions
Published: June 29th 2020 | Updated: September 28th 2024
FDA Approves Frontline Pembrolizumab for MSI-H/dMMR CRC
Published: March 14th 2024 | Updated: September 28th 2024
Fitting ADC Therapy Into the Treatment Paradigm in Advanced Bladder Cancer
Published: August 22nd 2023 | Updated: September 28th 2024
Sacituzumab Govitecan Continues to Show Efficacy in Pretreated mUC
Published: August 29th 2022 | Updated: September 28th 2024
POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?